Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30818349 | 0.93 | GRM5 (0.39) | GRM5L3MBTL1POLBPTGES2CYP11B1 | |
| SCHEMBL726239 | 0.93 | GRM5 (0.39) | GRM5L3MBTL1POLBPTGES2CYP11B1 | |
| SCHEMBL19912184 | 0.85 | TNKS (0.34) | GRM5DRD2 | |
| SCHEMBL19009978 | 0.83 | GRM5 (0.33) | GRM5DRD1 | |
| SCHEMBL13681621 | 0.82 | SCN9A (0.37) | GRM5DRD2 | |
| SCHEMBL12661284 | 0.82 | PKM (0.39) | GRM5L3MBTL1POLBPTGES2PKM | |
| SCHEMBL1224769 | 0.81 | CYP11B1 (0.33) | GRM5PKMCYP11B1CYP11B2DRD1 | |
| SCHEMBL12446372 | 0.81 | PTGER3 (0.36) | GRM5L3MBTL1POLBPKMPTGER3 | |
| SCHEMBL17426088 | 0.79 | DRD1 (0.33) | L3MBTL1LMNADRD1 | |
| SCHEMBL16449685 | 0.76 | HTR1A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758457-B2 | Water-insoluble ruthenium catalyst composition for use in aqueous hydrogenation reactions | DEXLECHEM GMBH (DE) | 2017-09-12 | — | — | US | disclosed |
| US-20160355454-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | DEXLECHEM GMBH (DE) | 2016-12-08 | — | — | US | disclosed |
| US-9433937-B2 | Water-insoluble ruthenium catalyst composition for use in aqueous hydrogenation reactions | DEXLECHEM GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20160008803-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | DEXLECHEM GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| US-8791300-B2 | Process for preparing a substituted dimethyl-(3-arylbutyl)amine compound by homogeneous catalysis | GRUENENTHAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008803-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | KRAS, PWWP2B, WIZ | GRM5 2511/4885L3MBTL1 4724/4885POLB 136/4885 |
| US-20160355454-A1 | WATER-INSOLUBLE RUTHENIUM CATALYST COMPOSITION FOR USE IN AQUEOUS HYDROGENATION REACTIONS | KRAS, PWWP2B, WIZ | GRM5 2511/4885L3MBTL1 4724/4885POLB 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.